"Treatment with henagliflozin is linked to an increase in the length of telomeres, chromosomal caps that shorten over time."
"A drug prescribed to people with type 2 diabetes can do more than lower blood sugar - it also helps to slow cellular aging, according to a clinical trial."
Henagliflozin treatment is associated with increased telomere length. Telomeres are chromosomal caps that progressively shorten with cell divisions and aging. Clinical-trial evidence links a drug prescribed for type 2 diabetes to both blood-sugar reduction and slowed cellular aging. The observed telomere lengthening indicates a potential geroprotective effect beyond glycemic control. These findings suggest that SGLT2 inhibitor therapy may influence molecular markers of aging in addition to metabolic outcomes. Further investigation is needed to confirm persistence of telomere changes, understand underlying mechanisms, and determine clinical significance for long-term health and age-related disease risk. Implications include potential adjustments to treatment strategies and priorities for longitudinal studies assessing clinical benefits.
Read at Nature
Unable to calculate read time
Collection
[
|
...
]